Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)

NCT06923826 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Salivary Gland Cancer
Thyroid Cancer

Interventions

DRUG: Sacituzumab govitecan

Sponsor

National University Hospital, Singapore

Collaborators

[object Object]